Top Story: University of Minnesota tests drug against deadly fungal infection

Researchers at the University of Minnesota Medical School have been looking for a less toxic treatment for cryptococcal meningitis, a fungal brain infection that is the leading cause of death worldwide in people with  human immunodeficiency virus (HIV). But a recent trial of an experimental antifungal drug performed by the team is showing promising results. The condition is currently treated with intravenous amphotericin, which is extremely harsh.

Research shows that the liquid form of the experimental drug is equally effective with fewer side effects. David Boulware, MD, MPH, an infectious disease expert leading the trial said, “If it works for the most severe life-threatening fungal infection, it should work for other fungal infections. That’s the key. It’s a potential revolution in fighting fungal infections.” The trial was conducted in Africa with 90% of patients surviving longer than those who take the intravenous drug. These results are outstanding, as about a third of patients hospitalized with this infection in Africa die within two weeks. However, most people don’t suffer any health problems when exposed to cryptococcus fungal strains, but they can be deadly for those with HIV or other conditions that weaken your immune system.

You can read more about the study here.